6 Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I
et al. Tumor immunogenicity determines the effect of B7 co-
stimulation on T cell-mediated tumor immunity. J Exp Med
1994; 179: 523–532.
7 Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I,
Hellstrom KE. B7-1/CD80-transduced tumor cells elicit
better systemic immunity than wild-type tumor cells
admixed with Corynebacterium parvum. Cancer Res 1994;
8 Felzmann T, Ramsey WJ, Blaese RM. Anti-tumor immunity
generated by tumor cells engineered to express B7-1 via
retroviral or adenoviral gene transfer. Cancer Lett 1999; 135:
9 Hurwitz AA, Townsend SE, Yu TF, Wallin JA, Allison JP.
Enhancement of the anti-tumor immune response using a
combination of interferon-gamma and B7 expression in an
experimental mammary carcinoma. Int J Cancer 1998; 77:
10 Martin-Fontecha A, Moro M, Crosti MC, Veglia F,
Casorati G, Dellabona P. Vaccination with mouse mammary
adenocarcinoma cells coexpressing B7-1 (CD80) and B7-2
(CD86) discloses the dominant effect of B7-1 in the induction
of antitumor immunity. J Immunol 2000; 164: 698–704.
11 Takahashi T, Hirano N, Takahashi T, Chiba S, Yazaki Y,
Hirai H. Immunogene therapy against mouse leukemia using
B7 molecules. Cancer Gene Therapy 2000; 7: 144–150.
12 Townsend SE, Allison JP. Tumor rejection after direct co-
stimulation of CD8+ T cells by B7-transfected melanoma
cells. Science 1993; 259: 368–370.
13 Townsend SE, Su FW, Atherton JM, Allison JP. Specificity
and longevity of antitumor immune responses induced by
B7-transfected tumors. Cancer Res 1994; 54 : 6477–6483.
14 Vasilevko V, Ghochikyan A, Sadzikava N, Petrushina I,
Tran M, Cohen EP et al. Immunization with a vaccine that
combines the expression of MUC1 and B7 co-stimulatory
molecules prolongs the survival of mice and delays the
appearance of mouse mammary tumors. Clin Exp Metastasis
2003; 20: 489–498.
15 Yang G, Hellstrom KE, Hellstrom I, Chen L. Antitumor
immunity elicited by tumor cells transfected with B7-2, a
second ligand for CD28/CTLA-4 co-stimulatory molecules.
J Immunol 1995; 154: 2794–2800.
16 Ge NL, Ye SL, Zheng N, Sun RX, Liu YK, Tang ZY.
Prevention of hepatocellular carcinoma in mice by IL-2 and
B7-1 genes co-transfected liver cancer cell vaccines. World J
Gastroenterol 2003; 9: 2182–2185.
17 Hull GW, McCurdy MA, Nasu Y, Bangma CH, Yang G,
Shimura S et al. Prostate cancer gene therapy: comparison
of adenovirus-mediated expression of interleukin 12
with interleukin 12 plus B7-1 for in situ gene therapy and
gene-modified, cell-based vaccines. Clin Cancer Res 2000; 6:
18 Mukherjee S, Nelson D, Loh S, van Bruggen J, Palmer LJ,
Leong C et al. The immune anti-tumor effects of GM-CSF
and B7-1 gene transfection are enhanced by surgical
debulking of tumor. Cancer Gene Therapy 2001; 8: 580–588.
19 Qian HN, Liu GZ, Cao SJ, Feng J, Ye X. The experimental
study of ovarian carcinoma vaccine modified by human B7-1
and IFN-gamma genes. Int J Gynecol Cancer 2002; 12:
20 Tatsumi T, Takehara T, Kanto T, Kazushita H, Ito A,
Kasahara A et al. B7-1 (CD80)-gene transfer combined with
interleukin-12 administration elicits protective and therapeu-
tic immunity against mouse hepatocellular carcinoma.
Hepatology 1999; 30: 422–429.
21 Jang YJ, Nam SY, Kim MS, Seong RH, Park YS,
Chung YH et al. Simultaneous expression of allogenic class
II MHC and B7.1 (CD80) molecules in A20 B-lymphoma cell
line enhances tumor immunogenicity. Mol Cells 2002; 13:
22 Pulaski BA, Ostrand-Rosenberg S. Reduction of established
spontaneous mammary carcinoma metastases following
immunotherapy with major histocompatibility complex class
II and B7.1 cell-based tumor vaccines. Cancer Res 1998; 58:
23 LeibundGut-Landmann S, Waldburger JM, Krawczyk M,
Otten LA, Suter T, Fontana A et al. Mini-review: Specificity
and expression of CIITA, the master regulator of MHC class
II genes. Eur J Immunol 2004; 34: 1513–1525.
24 Ting JP, Trowsdale J. Genetic control of MHC class II
expression. Cell 2002; 109: S21–S33.
25 Girdlestone J. Synergistic induction of HLA class I expres-
sion by RelA and CIITA. Blood 2000; 95: 3804–3808.
26 Liu A, Takahashi M, Toba K, Zheng Z, Hashimoto S,
Nikkuni K et al. Regulation of the expression of MHC class
I and II by class II transactivator (CIITA) in hematopoietic
cells. Hematol Oncol 1999; 17: 149–160.
27 Martin BK, Chin KC, Olsen JC, Skinner CA, Dey A, Ozato
K et al. Induction of MHC class I expression by the MHC
class II transactivator CIITA. Immunity 1997; 6: 591–600.
28 Martin BK, Frelinger JG, Ting JP. Combination gene
therapy with CD86 and the MHC class II transactivator in
the control of lung tumor growth. J Immunol 1999; 162 :
29 Armstrong TD, Clements VK, Martin BK, Ting JP,
Ostrand-Rosenberg S. Major histocompatibility complex
class II-transfected tumor cells present endogenous antigen
and are potent inducers of tumor-specific immunity. Proc
Natl Acad Sci USA 1997; 94: 6886–6891.
30 Meazza R, Comes A, Orengo AM, Ferrini S, Accolla RS.
Tumor rejection by gene transfer of the MHC class II
transactivator in murine mammary adenocarcinoma cells.
Eur J Immunol 2003; 33: 1183–1192.
31 Campbell MJ, Wollish WS, Lobo M, Esserman LJ.
Epithelial and fibroblast cell lines derived from a sponta-
neous mammary carcinoma in a MMTV/neu transgenic
mouse. In vitro Cell Dev Biol Anim 2002; 38: 326–333.
32 Morgenstern JP, Land H. Advanced mammalian gene
transfer: high titre retroviral vectors with multiple drug
selection markers and a complementary helper-free packa-
ging cell line. Nucleic Acids Res 1990; 18: 3587–3596.
33 Pear WS, Nolan GP, Scott ML, Baltimore D. Production of
high-titer helper-free retroviruses by transient transfection.
Proc Natl Acad Sci USA 1993; 90: 8392–8396.
34 Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD,
Muller WJ. Expression of the neu protooncogene in the
mammary epithelium of transgenic mice induces metastatic
disease. Proc Natl Acad Sci USA 1992; 89: 10578–10582.
35 Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman LJ, Peterlin
BM. Major histocompatibility complex class II transcrip-
tional platform: assembly of nuclear factor Y and regulatory
factor X (RFX) on DNA requires RFX5 dimers. Mol Cell
Biol 2002; 22 : 5616–5625.
36 Jabrane-Ferrat N, Bloom D, Wu A, Li L, Lo D, Sreedharan
SP et al. Enhancement by vasoactive intestinal peptide of
gamma-interferon production by antigen-stimulated type 1
helper T cells. FASEB J 1999; 13: 347–353.
37 Attal J, Theron MC, Houdebine LM. The optimal use of
IRES (internal ribosome entry site) in expression vectors.
Genet Anal 1999; 15: 161–165.
Challenge with mammary tumor cells expressing MHC class II and CD80
N Jabrane-Ferrat et al
Cancer Gene Therapy